Indocyanine Green-Guided Lymphadenectomy During Robot-Assisted Pylorus and Vagus Nerve Preserving Gastrectomy for Early Gastric Cancer: A Single-Centre Study.
[BACKGROUND] Near-infrared (NIR) fluorescence imaging with indocyanine green (ICG) has been recently introduced for lymphatic mapping in robotic gastrectomy.
- 표본수 (n) 18
- p-value p = 0.010
- p-value p < 0.05
APA
Fan Y, Zhang C, et al. (2025). Indocyanine Green-Guided Lymphadenectomy During Robot-Assisted Pylorus and Vagus Nerve Preserving Gastrectomy for Early Gastric Cancer: A Single-Centre Study.. The international journal of medical robotics + computer assisted surgery : MRCAS, 21(5), e70116. https://doi.org/10.1002/rcs.70116
MLA
Fan Y, et al.. "Indocyanine Green-Guided Lymphadenectomy During Robot-Assisted Pylorus and Vagus Nerve Preserving Gastrectomy for Early Gastric Cancer: A Single-Centre Study.." The international journal of medical robotics + computer assisted surgery : MRCAS, vol. 21, no. 5, 2025, pp. e70116.
PMID
41044819
Abstract
[BACKGROUND] Near-infrared (NIR) fluorescence imaging with indocyanine green (ICG) has been recently introduced for lymphatic mapping in robotic gastrectomy.
[METHODS] Sixty-two patients with early gastric cancer (EGC) were divided into three groups, namely ICG-guided robotic group (G1; n = 18), conventional robotic group (G2; n = 24), and laparoscopic control group (control; n = 20). The primary endpoints were retrieved LNs, surgical outcomes, and postoperative complications.
[RESULTS] The G1 group retrieved more total LNs than the other two groups; however, this difference was not statistically significant (19.8 vs. 16.1 vs. 16.9, p = 0.197). However, there were statistical differences in perigastric LNs (15 vs. 10.5 vs. 11, p = 0.010). The G1 group had shorter surgical time than G2 (260 vs. 300 min, p < 0.05).
[CONCLUSION] ICG guided technology aids in achieving a more precise regional LN dissection during robotic gastrectomy for EGC, and is a valuable advancement for gastric cancer surgery.
[CLINICAL TRIAL REGISTRATION] Chinese Clinical Trial Registry (ChiCTR2500106082).
[METHODS] Sixty-two patients with early gastric cancer (EGC) were divided into three groups, namely ICG-guided robotic group (G1; n = 18), conventional robotic group (G2; n = 24), and laparoscopic control group (control; n = 20). The primary endpoints were retrieved LNs, surgical outcomes, and postoperative complications.
[RESULTS] The G1 group retrieved more total LNs than the other two groups; however, this difference was not statistically significant (19.8 vs. 16.1 vs. 16.9, p = 0.197). However, there were statistical differences in perigastric LNs (15 vs. 10.5 vs. 11, p = 0.010). The G1 group had shorter surgical time than G2 (260 vs. 300 min, p < 0.05).
[CONCLUSION] ICG guided technology aids in achieving a more precise regional LN dissection during robotic gastrectomy for EGC, and is a valuable advancement for gastric cancer surgery.
[CLINICAL TRIAL REGISTRATION] Chinese Clinical Trial Registry (ChiCTR2500106082).
MeSH Terms
Adult; Aged; Female; Humans; Male; Middle Aged; Gastrectomy; Indocyanine Green; Laparoscopy; Lymph Node Excision; Operative Time; Optical Imaging; Postoperative Complications; Pylorus; Robotic Surgical Procedures; Stomach Neoplasms; Surgery, Computer-Assisted; Treatment Outcome; Vagus Nerve
같은 제1저자의 인용 많은 논문 (5)
- Single-Cell sequencing investigation of endoplasmic reticulum stress-related genes in gastric cancer prognostic models and identification of NOX5 as a novel therapeutic target.
- Synergistic CRISPR/Cas12a-Nanozyme System for Iontronic Sensing of Site-Specific Septin9 Methylation.
- Noninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma.
- Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses.
- First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.